Phototherapy is among our most powerful weapons for fighting against chronic inflammatory skin diseases. Since the middle of the past century, numerous controlled studies of broadband UV-B, narrowband UV-B, and psoralen plus UV-A have demonstrated that phototherapy is highly effective in treating cutaneous diseases, such as psoriasis and atopic dermatitis. In 1981, the development of a new lamp that emits radiation predominantly between 340 and 400 nm was described, introducing the era of UV-A1 phototherapy.1 Three different dosage regimens of UV-A1 are distinguished: high-, medium-, and low-dose UV-A1, emitting 90 to 130, 30 to 89, and less than 30 J/cm2, respectively. In contrast to UV-B, which penetrates into the papillary dermis only, longer wavelengths in the UV-A region can reach the subcutis as well. In 1992, UV-A1 was first introduced as a highly potent treatment option for acute atopic dermatitis.2 Three years later, a letter reported that UV-A1 was capable of reducing skin sclerosis in patients with localized scleroderma (LS).3 Since then, a variety of case reports and uncontrolled open studies have been published on UV-A1 phototherapy for sclerotic skin diseases.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
UV-A1 phototherapy in superficial morphea. A, Several active lesions are present on the trunk of a patient before treatment. B, Complete clearance of all lesions after 40 cycles of UV-A1 phototherapy. Posttreatment photographs were performed 3 months after the end of phototherapy.
UV-A1 phototherapy in extragenital lichen sclerosus. A, Clinical aspects of a patient with widespread extragenital lichen sclerosus on the left mamma. B, Almost complete clearance of former lesions after 40 cycles of UV-A1 phototherapy. Posttreatment photographs were taken 6 months after the end of phototherapy.
UV-A1 irradiation units. A, UV-A1 irradiation bed (Sellamed 24000; Sellas Medizinische Geräte, Gevelsberg, Germany) for phototherapy of the whole body. B, Portable UV-A1 irradiation device (Sellasol 3000; Sellas Medizinische Geräte) for phototherapy of circumscribed portions of the skin. This device was constructed to allow patients to perform phototherapy at home.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.